About Ophthalmology sector in China
The Ophthalmology sector in China comprises 84 companies, including 58 funded companies having collectively raised $800M in venture capital money and private equity. Out of these, 35 are Series A+ funded.
Ophthalmology sector in China has seen 5 IPOs. This represents almost 6.0% of all such companies - which is higher than the 5.0% exit rate of tech companies in general.
This sector includes medical devices, diagnostics tests, and pharmaceuticals for the diagnosis and treatment of ophthalmological disorders.
Ophthalmology sector is also known as Ophthalmic Devices, Eye Care or Vision Care.
Medical devices, diagnostics tests, and pharmaceuticals for the diagnosis and treatment of ophthalmological disorders are included in this sector. Healthcare Service Providers, Digital Health Solutions (software, apps, online platforms) are excluded.
Top Ophthalmology Companies in China
There are 84 Ophthalmology startups in China which include Remegen, Eluminex Biosciences, VivaVision Biotech, Frontera Therapeutics, Wuhan Ruijian Pharmaceutical Technology. Out of these, 58 startups are funded, with 35 having secured Series A+ funding.
Over the past 10 years, an average of 4 new companies have been launched annually. Notably, several of these startups have been founded by alumni of Columbia University, Hong Kong University of Science and Technology (HKUST) and Peking University.
Here is the list of top Ophthalmology startups in China
1. Remegen
Remegen is a developer of therapies for the treatment of cancer, autoimmune and eye diseases. Its technology is based on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies therapies. The platform has developed drug candidate R18 that is the fusion protein for the rheumatoid arthritis treatment.
Key facts about Remegen
- Founded Year: 2008
- Location: Yantai (China)
- Stage: Public
- Total Funding till date: $100M
- Investors: Lilly Asia Ventures, Orbimed and 10 Others
- Latest Funding Round: PE, Mar 16, 2020, $*****
- Tracxn Score: 62/100 What is this?
- Competitors Rank: 154 of 3,961 Competitors
Developer of therapeutics for ocular disorders. It offers a pipeline of drug candidates EB-101 for wet AMD, EB-102 for diabetic macular edema, EB-105 for retinal vascular diseases, EB-108 for wet AMD, and others.
Key facts about Eluminex Biosciences
- Founded Year: 2019
- Location: Suzhou (China)
- Stage: Series B
- Total Funding till date: $90M
- Investors: Lilly Asia Ventures, Quan Capital and 6 Others
- Latest Funding Round: Series B, Feb 27, 2023, $*****
- Tracxn Score: 52/100 What is this?
- Competitors Rank: 29 of 117 Competitors
Developer of therapeutic solutions for treating multiple eye diseases. The company has developed a drug candidate VVN001 that helps in treating dry eye diseases such as e dryness, foreign body sensation, burning, itching, photophobia, jealousy, and blurred vision. Other products include VVN349 for atopic dermatitis, VVN460 for psoriasis, VVN539 for glaucoma, and many more.
Key facts about VivaVision Biotech
- Founded Year: 2016
- Location: Pudong (China)
- Stage: Series E
- Total Funding till date: $46M
- Investors: Sequoia Capital China, Viva BioInnovator and 6 Others
- Latest Funding Round: Series E, Dec 15, 2023, $*****
- Tracxn Score: 52/100 What is this?
- Competitors Rank: 6 of 54 Competitors
Developer of AAV-based gene therapies for the treatment of rare and chronic diseases. The company focuses on developing recombinant AVV products for the treatment of genetic disorders including those of ophthalmology, liver, metabolic, and neuromuscular diseases.
Key facts about Frontera Therapeutics
- Founded Year: 2019
- Location: Suzhou (China)
- Stage: Series B
- Total Funding till date: $195M
- Investors: Sequoia Capital China, Boyu Capital and 4 Others
- Latest Funding Round: Series B, Jun 24, 2022, $*****
- Tracxn Score: 51/100 What is this?
- Competitors Rank: 524 of 3,492 Competitors
Developer of cell therapies to treat neurological and ophthalmological diseases. The company focuses on the development of a new generation of chemically induced cell therapy products, for untreatable diseases, such as Parkinson's disease and blindness. The company's product pipeline includes NN001 and NN002 for neurological disorders, NS001, and NS001 for diabetic neuropathy and optic neuropathy.
Key facts about Wuhan Ruijian Pharmaceutical Technology
- Founded Year: 2017
- Location: Wuhan (China)
- Stage: Series B
- Total Funding till date: $40M
- Investors: Fortune Capital, NLVC and 1 Other
- Latest Funding Round: Series B, Sep 04, 2025, $*****
- Tracxn Score: 51/100 What is this?
- Competitors Rank: 8 of 78 Competitors
Companies founded year-on-year in the Ophthalmology sector in China
11 Ophthalmology startups in China were founded in 2017 - this is the most number of startups founded in any year in the last 10 years.
- Total Number of Companies
Year | No. of companies |
|---|---|
2026 | - |
2025 | - |
2024 | - |
2023 | 1 |
2022 | 6 |
2021 | 7 |
2020 | 7 |
2019 | 7 |
2018 | 10 |
2017 | 11 |
Stage-wise distribution of Ophthalmology sector companies in China
Out of the total 84 Ophthalmology companies in China, 58 have secured funding. Among them, 35 have reached Series A or higher, and 19 to Series B or beyond.
Founded - 84
Funded - 58
Series A+ - 35
Series B+ - 19
Series C+ - 11
Company Stage | No. of companies |
|---|---|
Founded | 84 |
Funded | 58 |
Series A+ | 35 |
Series B+ | 19 |
Series C+ | 11 |
Let us walk you through our Sectors and other offerings
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Funding Trends in the Ophthalmology sector in China
Total funding year-on-year in the Ophthalmology sector in China
The Ophthalmology sector in China saw a total funding of more than $800M in the last 10 years. The most amount of funding was in 2022 at more than $242M.
- Total Funding
Year | Total Funding |
|---|---|
2025 | $40.7M |
2024 | $69.2M |
2023 | $53.9M |
2022 | $242M |
2021 | $218M |
2020 | $150M |
2019 | - |
2018 | $22.8M |
2017 | $4.09M |
Recent Funding Rounds in Ophthalmology in China
In the year 2025, till September 2025, Ophthalmology companies in China have raised $40.7M in equity funding across 5 rounds.
In the same period last year (i.e. till September 2024), Ophthalmology companies in China had raised $41.6M across 11 rounds.
So, 2025 has seen a 2.29% drop in funding in Ophthalmology companies in China as compared to 2024.
Here are some recent, important funding rounds in Ophthalmology companies in China:
Company | Round Raised | Amount Raised | Funding Date | Investors |
|---|---|---|---|---|
Series B | 4740 | Sep 04, 2025 | ||
Series A | 3545 | Aug 18, 2025 | ||
Series A | 7249 | Jun 14, 2025 | and 2 more | |
Series A | 4878 | Jun 12, 2025 | ||
Series A | 7317 | Feb 05, 2025 | - |
Top Investors in Ophthalmology in China
Orbimed is the top investor in Ophthalmology companies in China based on number of companies invested.
Here are some top investors in Ophthalmology companies in China:
Investor | Location | Top Portfolio Companies |
|---|---|---|
New York City (United States) | ||
Hellerup (Denmark) | - | |
Washington, DC (United States) | - | |
New York City (United States) | - | |
Chaoyang (China) | - |
IPOs in Ophthalmology in China
In the year 2022, till December 2022, 2 IPOs happened in Ophthalmology sector in China.
Here are some recent, important IPOs in Ophthalmology sector in China:
Company | IPO Date | Exchange Symbol |
|---|---|---|
Dec 12, 2022 | Hong Kong Exchanges (HKG) | |
Apr 01, 2022 | Shanghai Stock Exchange (SSE) | |
Dec 16, 2021 | Hong Kong Exchanges (HKG) | |
Apr 29, 2021 | Hong Kong Exchanges (HKG) | |
Nov 09, 2020 | Hong Kong Exchanges (HKG) |
Colleges which produce the most Ophthalmology companies in China
Companies founded by alumni from top colleges in the Ophthalmology in China
Most number of Ophthalmology startups in China have been founded by alumni from Columbia University, Hong Kong University of Science and Technology (HKUST) and Peking University.
College | No. of companies |
|---|---|
Columbia University | 1 |
Hong Kong University of Science and Technology (HKUST) | 1 |
Peking University | 1 |
Tsinghua University | 1 |
Top News in Ophthalmology in China
•
•
•
RemeGen's Bispecific Antibody RC148 Approved for Phase II Trial in US by FDAPR Newswire•Aug 08, 2025•FDA, Remegen
•
RemeGen's Telitacicept Receives EMA Orphan Drug Designation for Myasthenia GravisPR Newswire•Jun 17, 2025•Remegen
•
VivaVision to advance non-steroidal therapy in Phase III following Phase II winClinical Trials Arena•Dec 04, 2024•VivaVision Biotech
•
•
•
•
•
